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Cyclin A has in some studies been associated with poor breast cancer survival, although all studies have not confirmed
this. Its prognostic significance in breast cancer needs evaluation in larger studies. Tissue microarray (TMA) technique allows a
simultaneous analysis of large amount of tumours on a single microscopic slide. This makes a rapid screening of molecular markers in
large amount of tumours possible. Because only a small tissue sample of each tumour is punched on an array, the question has arisen
about the representativeness of TMA when studying markers that are expressed in only a small proportion of cells. For this reason,
we wanted to compare cyclin A expression on TMA and on traditional large sections. Two breast cancer TMAs were constructed of
200 breast tumours diagnosed between 1997–1998. TMA slides and traditional large section slides of these 200 tumours were
stained with cyclin A antibody and analysed by two independent readers. The reproducibility of the two readers’ results was good or
even very good, with kappa values 0.71–0.87. The agreement of TMA and large section results was good with kappa value 0.62–
0.75. Cyclin A overexpression was significantly (Po0.001) associated with oestrogen receptor and progesterone receptor negativity
and high grade both on TMA and large sections. Cyclin A overexpression was significantly associated with poor metastasis-free
survival both on TMA and large sections. The relative risks for metastasis were similar on TMA and large sections. This study suggests
that TMA technique could be useful to study histological correlations and prognostic significance of cyclin A on breast cancer on a
large scale.
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Breast cancer is a heterogeneous disease. Differences in tumour
phenotypes lead to varying aggressiveness and ability to respond
to a given treatment. Nowadays, breast tumours are classified not
only by their morphological but also by immunohistochemical and
molecular genetic characteristics.
Tissue microarray (TMA) technique was developed by Kononen
et al (1998). This technique allows rapid screening of multiple
stainings of large amount of tumours. In TMA technology, tissue
cylinders (diameter 0.6mm) are punched from hundreds of
different tumour blocks and brought into a recipient TMA block.
Sections of the blocks can then be used in simultaneous analysis of
all the tumours on DNA, RNA and protein level. Tissue microarray
technique only takes out a small, cylindrical specimen from the
donor block. This minimises the tissue damage to the donor block
and allows its use in many studies, but still leaves a virtually
undamaged tissue block for the pathologist.
In TMA, only a small amount of tumour (0.6mm) is analysed,
leading to the question of how representative the minute tissue on
TMA is and how much tumour heterogeneity affects the results.
Many studies have shown that although a result of an individual
tumour on TMA and on a large section may vary, the correlation to
histopathological factors and prognostic implications are similar
when large numbers of tumours are studied (Kononen et al, 1998;
Camp et al, 2000; Gillett et al,2 0 0 0 ;N o c i t oet al, 2001; Torhorst et al,
2001). In breast cancer, the expression of known prognostic and
predictive factors such ER (oestrogen receptor), PR (progesterone
receptor) and HER2 (human epidermal growth factor receptor 2)
were reliably analysed on TMA (Kononen et al, 1998; Camp et al,
2000; Gillett et al, 2000; Torhorst et al, 2001), but it is still unclear as
to how representative TMA is when molecules that show focal
localisation within the tumour are studied (Gillett et al,2 0 0 0 ) .
More than 80% of breast cancer patients are alive 5 years after the
initial diagnosis (Finnish Cancer Registry, 2002). The best estab-
lished prognostic factors are tumour size and the number of the
involved regional lymph nodes (Singletary et al, 2003). Grade of the
tumour, hormone receptor (ER, PR) status and proliferation rate are
also well-documented prognostic factors, especially in node-negative
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sdisease (Ross and Fletcher, 1999; Schnitt, 2001). Of these factors,
only ER, PR and proliferation rate predict treatment efficacy.
Expression of ER or PR is a prerequisite for endocrine responsive-
ness (EBCTCG, 2005), whereas a high proliferation rate predicts a
more favourable chemotherapy response (Hietanen et al, 1995).
The best documented method of measuring proliferation in
breast cancer is SPF (S-phase fraction) assessed by flow-cytometry
(Sigurdsson et al, 1990). The method is, however, cumbersome and
requires fresh tissue. In recent years, immunohistochemistry has
gained popularity for the assessment of proliferation. Ki-67 is the
most studied proliferation antigen, but there still is no consensus
on methodology or cutoff values for prognostification in breast
cancer (Colozza et al, 2005). Cyclins are cell cycle regulators
overexpressed in several tumours including breast cancer
(Parwaresch and Rudolph, 1996). Cyclin A is required for
replication during the S-phase and is also expressed in the early
mitotic phase (G2) of the cell cycle controlling the cell entry into
mitosis (Parwaresch and Rudolph, 1996). In three previous studies
in sarcomas and head and neck cancer, cyclin A was associated
with prognosis and chemotherapy response even stronger than
Ki-67 (Huuhtanen et al, 1999a,b; Saarilahti et al, 2003). Several
studies have shown an association between overexpression of
cyclin A and poor survival in breast cancer (Bukholm et al,
2003a,b, 2001; Michalides et al, 2002; Michels et al, 2003), whereas
one study did not confirm it (Kuhling et al, 2003; Rudolph et al,
2003). Further studies with a larger number of patients are needed,
including also specific groups of patients like those with hereditary
predisposition to breast cancer. Tissue microarray seems a
tempting method to evaluate cyclin A expression on breast
tumours. Cyclins D1 and E have been studied on TMA (Richter
et al, 2000; Han et al, 2003; Hedberg et al, 2003; Jirstrom et al,
2003; Schraml et al, 2003; Stendahl et al, 2004). However, cyclin A
has not yet been analysed on breast cancer TMA. In this study, we
evaluated cyclin A expression of 200 breast tumours on TMA and
large sections in order to evaluate the representativity of TMA for
the assessment of proliferation compared to large sections.
MATERIALS AND METHODS
Patients
Tumours from 200 breast cancer patients, treated in Helsinki
University Central Hospital between 1997 and 1998 (Syrjakoski et al,
2000), were analysed on TMA and traditional large sections.
Pathology reports of the primary tumours were studied. Patholo-
gical data including information on tumour histology, grade, ER and
PR status, tumour diameter, nodal status and distant metastases
were collected. Grading was performed according to Scarff–Bloom–
Richardson modified by Elston and Ellis (1991). Patients’ records
were studied and information on adjuvant treatment, local relapse
and distant metastases as well as time of death or follow-up were
collected. Patient characteristics are shown in Table 1.
Tissue microarray construction
Paraffin blocks of primary tumours of the patients were collected.
Haematoxylin and eosin sections of the original blocks were
studied and the most representative area of each tumour was
punched and brought into two recipient paraffin blocks to produce
two breast cancer microarrays, including four cores (diameter
0.6mm) of each tumour. Then, 3- to 4-mm- thick sections were
then cut from array blocks and transferred to glass slide (Eerola
et al, 2005; Tommiska et al, 2005).
Immunohistochemistry
Formalin-fixed paraffin-embedded tissue material from the blocks
used for TMA sampling from each of the 200 tumours and their
corresponding TMA slides were cut in 3- to 4-mm-thick sections
and deparaffinised. Immunostaining for cyclin A (mouse mono-
clonal; Novo Castra Laboratories) was carried out manually.
Antigen retrieval was carried out using a pressure cooker for 5min
in 0.01 M citrate buffer, pH 6.0. Primary antibody was diluted
1:300 and applied for overnight incubation. Staining was carried
out using the avidin–biotin peroxidase complex and AEC
procedures (Wood and Warnke, 1981). The peroxidase was
developed using the DAB technique.
Two readers (KA and CA) scored all slides. The percentage of
cyclin A-positive breast cancer cells was counted in one high-
power field ( 40 objective) in each of the four tissue cores on
TMA and in three randomly selected and one ‘hot-spot’ high-
power field on large sections. A minimum of 200 breast cancer
cells and in most cases at least 400 breast cancer cells were counted
from each tumour. To better demonstrate the pathological
associations, results were dichotomised at a cutoff value of 10%
(Poikonen et al, 2005). All statistical evaluations were carried out
with both average and maximal values of the four counts.
Statistical analysis
All statistical analyses were made using Macintosh SPSS 11
statistical software package. Correlations of TMA and large section
results as well as correlations of two independent readers’ results
were evaluated by crosstabs and by a scatter diagram showing the
differences of the results plotted against the average of the results.
Kappa values were counted to evaluate the reproducibility of the
results by two readers and by two different methods. Student’s t-
test for independent samples was used to analyse whether
disconcordant results on large section and TMA or between the
two readers was owing to a low number of cells counted.
Correlation of cyclin A expression to ER, PR, nodal status and
grade were analysed by the nonparametric Spearman’s correlation
coefficient. All statistical tests of the association of cyclin A and
clinical parameters as well as survival analysis with the Cox
proportional-hazard model were performed with cyclin A percen-
tage as a continuous variable. To improve readability, relative risks
Table 1 Patient characteristics
Grade T
1 47 (23.5%) 1 111 (55.5%)
2 86 (43.0%) 2 71 (35.5%)
3 58 (29.0%) 3 6 (3.0%)
Not known 9 (4.5%) 4 7 (3.5%)
Not known 5 (2.5%)
NM
Node positive 96 (48.0%) 0 190 (95.0%)
Node negative 98 (49.0%) 1 9 (4.5%)
Not known 6 (3.0%) Not known 1 (0.5%)
Oestrogen receptor Progesterone receptor
Positive 155 (77.5%) Positive 137 (68.5%)
Negative 35 (17.5%) Negative 53 (26.5%)
Not known 10 (5.0%) Not known 10 (5.0%)
Local relapse Distant metastases
Yes 22 (11.0%) Yes 49 (24.5%)
No 178 (89.0%) No 151 (75.5%)
Adjuvant radiotherapy Adjuvant chemotherapy
Yes 173 (86.5%) Yes 78 (39.0%)
No 27 (13.5%) No 122 (61.0%)
Adjuvant hormone therapy
Yes 91 (45.5%)
No 109 (54.5%)
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a cutoff of 10%.
RESULTS
On TMA, results of 14 tumours (7%) were missing, five of them
owing to loss of all four punches during the staining and nine
because of lack of tumour in the arrayed samples. On large
sections, result of only one tumour (0.5%) was missing, and the
reason was unsuccessful staining. The median cyclin A count 3.7%
(range 0–34.4%) on TMA average values, 5.8% (0–52.9%) on TMA
maximum values, 4.3% (0–32.1%) on large section average values
and 9.0% (0–39.1%) on large section maximum values.
Agreement of readers’ results
Figures 1 and 2 show scatter diagrams of the differences of two
readers’ results. The mean difference between the two readers
scoring and 95% limits of agreement were 0.1% ( 4.8 to þ5.1%)
for TMA average values, 0.4% ( 8.0 to þ8.8%) for TMA
maximum values, 0.4% ( 4.4 to þ5.1%) for large section average
values and 1.0% ( 7.5 to þ9.5%) for large section maximum
values. The kappa values evaluating the reproducibility two
readers’ results were 0.87 for TMA average value, 0.83 for TMA
maximum value, 0.71 for large section average value and 0.80 for
large section maximum value. The concordance of the positive and
the negative results for the two readers with 10% as a cutoff point
is shown in Table 2. In order to evaluate possible reasons for
discrepant results of the two readers, we calculated the mean
number of nuclei counted for concordant vs discrepant cases. The
mean number is the mean of the two readers results. The mean
number of nuclei counted was 661 in concordant tumours and 420
in discrepant tumours (P¼0.002) for array average values, 671 in
concordant tumours and 410 in discrepant tumours (Po0.0005)
for array maximum values, 767 in concordant tumours and 465 in
discrepant tumours (Po0.0005) for large section average values
and 759 in concordant tumours and 518 in discrepant tumours for
large section maximum values (Po0.0005).
Agreement of TMA and large sections on cyclin A staining
Tissue microarray and large section cyclin A results were
compared using the average values of the two readers’ results.
Figure 3 shows a scatter diagram of the differences of TMA and
large section results. The mean difference between the TMA and
large section scoring and 95% limits of agreement were 0.4% ( 6.9
to þ7.6%) for average values and 2.0% ( 8.7 to þ12.6%) for
maximum values. The kappa values were 0.75 for average values
and 0.62 for maximum values. The agreement for classification of a
high cyclin A score between TMA and sections is shown in Table 3.
The mean amount of nuclei counted was 683 in concordant
tumours and 308 in discrepant tumours for average values
(Po0.0005). For maximum values, the mean amount of cells
counted in concordant tumours was 661 and 612 in discrepant
tumours (P¼0.33).
When associations of cyclin A and histological variables were
studied, the results on TMA and large sections were well in
concordance. High cyclin A expression associated strongly with ER
negativity (Po0.0005), PR negativity (Po0.0005) and high grade
(Po0.0005). The associations were similar when cyclin A
expression was analysed with TMA maximum value, TMA average
value, large section maximum value and large section average
value (Table 4). Cyclin A expression was not associated with nodal
status of the tumour.
Cyclin A overexpression was not statistically significantly
associated with overall survival; however, it was significantly
associated with poorer metastasis-free survival (Table 5).
DISCUSSION
In this study, we investigated cyclin A expression of 200 breast
tumours on TMA and on traditional large sections and we found
that the agreement between these methods is good, as well as the
reproducibility of the results by two independent readers. The
main aim of this study with a relatively small patient population of
200 patients was to evaluate the suitability of TMA analysis for a
larger scale study on the prognostic significance of cyclin A and
not to clarify the prognostic value of cyclin A overexpression. All
histological correlations, however, were similar on TMA and large
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Figure 1 (A) Scattergram shows the difference in two readers score
(KA CA) compared to mean score of the two readers (KAþCA/2) on
TMA average values. Lines indicate the 95% limits of agreement. (B)
Scattergram shows the difference in two readers score (KA CA)
compared to mean score of the two readers (KAþCA/2) TMA maximum
values. Lines indicate the 95% limits of agreement.
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metastasis-free survival can be evaluated on TMA as reliably as on
large sections.
To evaluate the reproducibility of cyclin A results, we first
compared the agreement of two readers’ results. The kappa value is
considered as a reliable tool to assess this agreement (Altman,
1991). The agreement is good if the kappa value is 0.61–0.80 and
very good if the kappa value is 0.81–1.00 (Altman, 1991). We
found the reproducibility of cyclin A assessment for the two
readers to be good or very good both in large sections and TMAs.
As expected, the assessment of maximum proliferation rate using
hot-spots was less reproducible. One important reason for
disagreement seems to be the amount of tissues studied, as
discrepant findings seemed to be associated with low number of
nuclei counted. In a recent study, the reproducibility of
malignancy grading was only moderately good (Meyer et al,
2005), suggesting that measurement of proliferation by immuno-
histochemically detectable markers will probably give superior
results. Our study shows that reproducibility of cyclin A
expression on TMA is good and it seems to be a method that
could easily be adapted to routine use.
As the results of two readers were in concordance, we counted
the average of the results of two readers and used these results to
analyse the concordance of TMA and large section results. The
agreement between cyclin A assessment on TMAs and large slides
was good for both mean and maximum value, but as expected
somewhat better for the former. Again, the average results that
differ most from each other were results of tumours with fewer
cells counted. The agreement was moderately weaker on maximum
than average values. One reason for this could be the method used
in counting cells: on TMA, one randomly selected high-power field
was counted on each punch, but on large sections, we searched one
‘hot-spot’ high-power field and selected the other three randomly.
Earlier studies in breast cancer TMA have shown good agreement
of ER, PR, p53 and HER2 between TMA and large sections (Camp
et al, 2000; Gillett et al, 2000; Torhorst et al, 2001). Expression of
cyclins E and D1 were in concordance in 94.3 and 95.4% of cases,
respectively, in a previous study of 175 breast tumours (Han et al,
2003). The proliferation marker Ki-67 was studied in a previous
bladder carcinoma study comprising 2317 cases and the con-
cordance of TMA and large sections was good (Nocito et al, 2001).
Cyclin E expression on TMA and large section has also been
evaluated in a series of 218 renal cell carcinomas and the
agreement was good (Po0.001) (Hedberg et al, 2003).
Cyclin A overexpression was associated with ER and PR
negativity and with high grade, in line with earlier studies
(Michalides et al, 2002; Michels et al, 2003). A high cyclin A score
was also prognostic for distant recurrence both in large sections
and TMAs. Most previous studies have shown association between
cyclin A overexpression and poor prognosis (Bukholm et al, 2001,
2003a; Michalides et al, 2002; Michels et al, 2003), whereas one
study failed to find an association (Kuhling et al, 2003; Rudolph
et al, 2003). Thus in concordance with other studies in various
malignancies, this study confirms that TMAs are well suited for
assessment of immunohistochemical markers even for antigens
with a variable expression in different parts of a tumour. The
similarity of clinicopathological associations on TMAs and large
sections also support the validity of TMA for scoring of cyclin A in
breast cancer.
Considering our results, we conclude that TMA is as good as
large sections in scoring for cyclin A on breast cancer.
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Figure 2 (A) Scattergram shows the difference in two readers score
(KA CA) compared to mean score of the two readers (KAþCA/2) on
large section average values. Lines indicate the 95% limits of agreement. (B)
Scattergram shows the difference in two readers score (KA CA)
compared to mean score of the two readers (KAþCA/2) on large
section maximum values. Lines indicate the 95% limits of agreement.
Table 2 Comparison of the results of two independent readers
TMA average results
Positive cells Negative cells
37 (20.4%) 3 (1.7%) Positive cells
5 (2.7%) 136 (75.1%) Negative cells
TMA maximum results
Positive cells Negative cells
57 (31.4%) 3 (1.7%) Positive cells
11 (6.1%) 110 (60.8%) Negative cells
Large section average results
Positive cells Negative cells
31 (15.6%) 10 (5.0%) Positive cells
10 (5.0%) 148 (74.4%) Negative cells
Large section maximum results
Positive cells Negative cells
74 (37.2%) 14 (7.0%) Positive cells
5 (2.5%) 106 (53.3%) Negative cells
TMA¼tissue microarray.
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Figure 3 (A) Scattergram shows the difference in array and large section
scores (array large section) compared to large section score on average
values. Lines indicate the 95% limits of agreement. (B) Scattergram shows
the difference in array and large section scores (array large section)
compared to large section score on maximum values. Lines indicate the
95% limits of agreement.
Table 3 Comparison of tissue microarray and large section results
Average results
Array, positive cells Array, negative cells
30 (16.1%) 8 (4.3%) Large section, positive cells
7 (3.8%) 141 (75.8%) Large section, negative cells
Maximum results
Array, positive cells Array, negative cells
53 (28.5%) 27 (14.5%) Large section, positive cells
7 (3.8%) 99 (53.2%) Large section, negative cells
Table 4 Cyclin A and correlation to histological variables
Spearman’s correlation coefficientP-value
ER
TMA average value  0.417 o0.0005
TMA maximum value  0.414 o0.0005
Large section average value  0.453 o0.0005
Large section maximum value  0.459 o0.0005
PR
TMA average value  0.427 o0.0005
TMA maximum value  0.427 o0.0005
Large section average value  0.474 o0.0005
Large section maximum value  0.450 o0.0005
Grade
TMA average value 0.529 o0.0005
TMA maximum value 0.537 o0.0005
Large section average value 0.555 o0.0005
Large section maximum value 0.523 o0.0005
Nodal status
TMA average value  0.078 0.295
TMA maximum value  0.065 0.384
Large section average value  0.046 0.539
Large section maximum value  0.023 0.762
TMA¼tissue microarray.
Table 5 Survival and cyclin A overexpression
Hazard for low vs high cyclin A
aP-value
b
(a) Overall survival
TMA average result 1.338 0.128
Large section average result 1.205 0.639
TMA maximum result 1.651 0.173
Large section maximum result 1.393 0.755
(b) Overall survival in multivariate analysis with adjuvant chemotherapy and hormone
therapy
TMA average result 1.580 0.051
Large section average result 1.540 0.503
TMA maximum result 1.915 0.076
Large section maximum result 1.194 0.534
(c) Metastasis free survival
TMA average result 1.765 0.026
Large section average result 1.831 0.117
TMA maximum result 1.858 0.022
Large section maximum result 1.463 0.021
(d) Metastasis free survival in multivariate analysis with adjuvant chemotherapy and
hormone therapy
TMA average result 2.100 0.009
Large section average result 1.950 0.075
TMA maximum result 2.149 0.009
Large section maximum result 1.528 0.019
aLow/high cut off value 10%.
bCyclin A analyzed as a continuous variable.
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